Skip to content
10-K

Annual Report

BioCrude Technologies USA, Inc.

0001731122-24-000503

← back to feed
Filed
Mar 27, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 29, 2024 50.82M sh
Current Assets FY 2023 · Dec 31, 2023 $0
Current Assets FY 2023 · Dec 31, 2022 $4.79K
Shares Diluted FY 2023 · Dec 31, 2022 50.73M sh
Capex FY 2023 · Dec 31, 2022 $1.1K
Operating Cash Flow restated FY 2023 · Dec 31, 2022 −$158.22K
Short Term Debt FY 2023 · Dec 31, 2022 $126K
Stockholders Equity FY 2023 · Dec 31, 2022 −$147K
Current Liabilities FY 2023 · Dec 31, 2022 $173.07K
Total Liabilities FY 2023 · Dec 31, 2022 $173.07K
Total Assets FY 2023 · Dec 31, 2022 $22.68K
Eps Diluted FY 2023 · Dec 31, 2022 $0.00
Eps Basic FY 2023 · Dec 31, 2022 $0.00
Sga Expense FY 2023 · Dec 31, 2022 $177.66K
Net Income FY 2023 · Dec 31, 2022 −$181.53K
Operating Income FY 2023 · Dec 31, 2022 −$177.66K